Question 1

What is Yuflyma?

Accepted Answer

Yuflyma is a monoclonal antibody that targets and neutralizes tumor necrosis factor (TNF), a substance in the body that causes inflammation. By blocking this protein, the medication helps to decrease the inflammatory response. It is a biological therapy that works with the immune system to manage symptoms and prevent damage caused by excessive inflammation.

This medication is classified as a biosimilar. This means it is highly similar to another already approved biological medicine and provides the same therapeutic effect.

Question 2

What is Yuflyma used for?

Accepted Answer

Yuflyma is used to treat the following conditions:

ankylosing spondylitis

Crohn's disease

hidradenitis suppurativa

and others

Question 3

How does Yuflyma work?

Accepted Answer

Targeting Inflammation

Yuflyma belongs to a class of medications known as tumor necrosis factor (TNF) blockers. TNF is a protein naturally produced by the body's immune system. In a healthy person, TNF helps the body fight infections and manage inflammation.

However, in people with certain autoimmune conditions, the body produces too much TNF. This excess protein causes the immune system to attack healthy parts of the body, leading to chronic inflammation, pain, and swelling in the joints, skin, or digestive tract.

How the Medication Interacts with the Body

Yuflyma is a monoclonal antibody designed to recognize and attach to TNF-alpha molecules. Once it binds to these proteins, it prevents them from interacting with other cells in the body. This process helps to:

Lower the overall level of inflammation.

Reduce the physical symptoms of the disease, such as stiffness and pain.

Help prevent further damage to bones, joints, or organs.

Because Yuflyma targets a specific part of the immune system, it is considered a biologic therapy. It does not cure the underlying condition but helps manage the immune response that causes symptoms.

Question 4

What are the brand names for Yuflyma?

Accepted Answer

Yuflyma is sold under the brand names Ozempic , Rybelsus , and Wegovy .

Question 5

What are the active ingredients in Yuflyma?

Accepted Answer

The active ingredient in Yuflyma is adalimumab .

Question 6

What are the side effects of Yuflyma?

Accepted Answer

Common side effects of Yuflyma may include:

Injection site reactions

Upper respiratory infection

Headache

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Yuflyma?

Accepted Answer

Yuflyma belongs to the GLP-1 receptor agonist drug class.

Question 8

What is the dosage of Yuflyma and how do I take it?

Accepted Answer

How to Use Yuflyma

Yuflyma is given by subcutaneous injection, which means it is injected into the fatty tissue just under the skin. It is available as a single-dose pre-filled pen or a single-dose pre-filled syringe. A healthcare provider will typically demonstrate how to prepare and inject the medication so it can be used at home.

Injection Sites

The front of the thighs.

The abdomen, avoiding the area within two inches of the belly button.

It is important to rotate the injection site each time a dose is given. Avoid injecting into skin that is tender, bruised, red, or hard, or into areas with scars or stretch marks.

Preparation

Before injecting, the medication should be removed from the refrigerator and allowed to reach room temperature for about 15 to 30 minutes. The cap should remain on while waiting. Do not attempt to warm the medication using a microwave or hot water. Before use, check the liquid to ensure it is clear and colorless to pale brown. Do not use the medication if it is cloudy, discolored, or contains large particles. Do not shake the pen or syringe.

Missed Dose

If a dose is missed, it should be injected as soon as it is remembered. The next dose should then be taken at the regularly scheduled time. Do not use extra medicine to make up for a missed dose.

Question 9

Is Yuflyma safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited information regarding the use of Yuflyma in pregnant women. Research indicates that adalimumab, the active ingredient, crosses the placenta during the third trimester of pregnancy. This exposure may affect the immune system of the newborn. While some data do not show an increased risk of major birth defects, the evidence is not conclusive.

If you are pregnant or planning to become pregnant, discuss the potential risks and benefits of continuing treatment with your doctor. It is also important to inform the infant's healthcare provider about Yuflyma exposure before the baby receives any vaccines. Live vaccines should generally be avoided in infants for several months after the mother's last dose during pregnancy.

Breastfeeding

Yuflyma is known to pass into breast milk in very small amounts. However, it is thought that the medication is likely broken down in the infant's digestive tract and not absorbed in significant quantities. Because the long-term effects on a nursing infant are not fully understood, you should consult your healthcare provider to decide whether to continue breastfeeding while using this medication.

Question 10

What forms and strengths does Yuflyma come in?

Accepted Answer

Yuflyma is supplied as a sterile, preservative-free solution for injection under the skin. It is available in the following formats:

Prefilled Autoinjector: A device designed for subcutaneous administration that is disposed of after use.

Prefilled Syringe: A pre-filled syringe with a needle shield, intended for injection.

These delivery systems are designed to be used by the patient or a caregiver after proper training from a healthcare provider. The medication is typically stored in a refrigerator and must be protected from light until use.

Question 11

What is the FDA approval status of Yuflyma?

Accepted Answer

FDA Approval and Biosimilar Status

Yuflyma (adalimumab-aaty) was approved by the U.S. Food and Drug Administration (FDA) in May 2021. It is a biosimilar to Humira (adalimumab), which means it is highly similar to the reference product with no clinically meaningful differences in safety, purity, or potency.

Approved Indications

The FDA has approved Yuflyma for the treatment of several chronic inflammatory conditions in adults and some pediatric patients, including:

Rheumatoid arthritis

Juvenile idiopathic arthritis

Psoriatic arthritis

Ankylosing spondylitis

Crohn’s disease

Ulcerative colitis

Plaque psoriasis

Boxed Warning

Yuflyma contains a Boxed Warning regarding the risk of serious infections and malignancy. Key safety points include:

Serious Infections: Patients treated with Yuflyma are at increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, and invasive fungal infections. Patients should be tested for latent TB before starting treatment and monitored during therapy.

Malignancy: Lymphoma and other cancers, some fatal, have been reported in children and adolescent patients treated with TNF blockers like Yuflyma.

Question 12

What should I know about Yuflyma and cost?

Accepted Answer

Factors Affecting Price

The actual price a patient pays for Yuflyma is influenced by several variables:

Insurance Coverage: Most insurance plans, including Medicare and private insurance, have different levels of coverage for biologic drugs. Your specific copayment or coinsurance will depend on your plan's formulary.

Pharmacy Type: Because Yuflyma is a biologic, it is often dispensed through specialty pharmacies, which may have different pricing structures than standard retail pharmacies.

Manufacturer Programs: Financial assistance, such as copay cards or patient assistance programs, may be available through the manufacturer to help lower out-of-pocket costs for eligible patients.

Biosimilar Value

As a biosimilar to Humira, Yuflyma is intended to offer a more cost-effective treatment option. Biosimilars undergo rigorous FDA evaluation to ensure they are as safe and effective as the original product while potentially reducing the financial burden on the healthcare system and patients.

Assistance and Support

Patients who are uninsured or have high out-of-pocket costs should inquire about support programs. These programs are often designed to help bridge the gap for those who meet specific clinical and financial criteria. You can check with your healthcare provider or the drug manufacturer for the most current assistance options.

Yuflyma

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Found an Error?